Adalimumab

Active ingredient description

Adalimumab binds specifically to TNF and neutralizes the biological function of TNF by blocking its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab also modulates biological responses that are induced or regulated by TNF, including changes in the levels of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 0.1-0.2 nM).

Medicine classification

This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:

ATC code
Group title
Classification
Adalimumab
L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AB Tumor necrosis factor alpha (TNF-α) inhibitors
Discover more medicines within L04AB04

Medicines

Adalimumab is the active ingredient of these drugs:

Drug
Countries

Australia Austria Brazil Cyprus Ecuador

Austria Estonia Ireland Lithuania Poland

Estonia Lithuania

Australia

Austria Estonia Lithuania Poland

Austria Estonia Ireland Lithuania Poland

Estonia Ireland Poland

Austria Ecuador Estonia Finland France

Australia Austria Brazil Canada Cyprus

Australia Austria Brazil Cyprus Ecuador

Australia Austria Brazil Cyprus Ecuador

Austria Cyprus Estonia Finland France

Estonia Lithuania Poland

Estonia Ireland Poland

Ecuador

Estonia Lithuania

Brazil

Estonia Finland Germany Ireland Lithuania

Product monographs

Medicine agencies around the world have authorized marketing of this active ingredient according to these medication package inserts (MPIs):

Title
Type
Country
Summary of Product Characteristics (SPC)
Summary of Product Characteristics (SPC)

2D molecular structure

2D representation of the active ingredient's molecular structure

Unique ingredient identifier (UNII)

FYS6T7F842 - ADALIMUMAB

CAS registry number

331731-18-1 - adalimumab

SNOMED-CT

407317001 - Adalimumab (substance)